WO2026064705A1 - Composés 5/5-5/6-bisaryles en tant qu'inhibiteurs de kinase activée par le facteur de croissance transformant béta - Google Patents

Composés 5/5-5/6-bisaryles en tant qu'inhibiteurs de kinase activée par le facteur de croissance transformant béta

Info

Publication number
WO2026064705A1
WO2026064705A1 PCT/US2025/047340 US2025047340W WO2026064705A1 WO 2026064705 A1 WO2026064705 A1 WO 2026064705A1 US 2025047340 W US2025047340 W US 2025047340W WO 2026064705 A1 WO2026064705 A1 WO 2026064705A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
nmr
mhz
dmso
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2025/047340
Other languages
English (en)
Inventor
Herman O. Sintim
Desmond AKWATA
Asmita ASMI
Neetu DAYAL
Mandeepkaur HUNJAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of WO2026064705A1 publication Critical patent/WO2026064705A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés 5/5-5/6 bisaryles qui inhibent la kinase activée par le facteur de croissance transformant β (TAK1) ; des compositions les comprenant ; et leur utilisation pour le traitement de cancers et de maladies inflammatoires.
PCT/US2025/047340 2024-09-23 2025-09-22 Composés 5/5-5/6-bisaryles en tant qu'inhibiteurs de kinase activée par le facteur de croissance transformant béta Pending WO2026064705A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202463697731P 2024-09-23 2024-09-23
US63/697,731 2024-09-23

Publications (1)

Publication Number Publication Date
WO2026064705A1 true WO2026064705A1 (fr) 2026-03-26

Family

ID=99168814

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2025/047340 Pending WO2026064705A1 (fr) 2024-09-23 2025-09-22 Composés 5/5-5/6-bisaryles en tant qu'inhibiteurs de kinase activée par le facteur de croissance transformant béta

Country Status (1)

Country Link
WO (1) WO2026064705A1 (fr)

Similar Documents

Publication Publication Date Title
CN113717156B (zh) Egfr抑制剂、其制备方法及用途
CN107108637B (zh) 三唑并嘧啶化合物及其用途
KR101828187B1 (ko) 신규 축합 피리미딘 화합물 또는 그 염
CA3124678A1 (fr) Inhibiteurs aza-heterobicycliques de mat2a et procedes d'utilisation pour le traitement du cancer
CN110167941B (zh) 取代的稠合杂芳基化合物作为激酶抑制剂及其应用
JP2019524872A (ja) 癌の治療に有用なイミダゾピリミジン化合物
JP2022526854A (ja) ホスファチジルイノシトール３－キナーゼ阻害剤
KR20140027902A (ko) 키나제 억제제로서 치환된 피라졸로-퀴나졸린 유도체
JPWO2008001886A1 (ja) オーロラ（Ａｕｒｏｒａ）阻害剤
CN109790158B (zh) 作为jak抑制剂杂环化合物，该化合物的盐类及其治疗用途
US20130065883A1 (en) Triazolo [4, 5- B] Pyridin Derivatives
JP2019522049A (ja) トリアゾロピリジン化合物及びその使用
CN105566321A (zh) 杂芳化合物及其在药物中的应用
CN112457306A (zh) 3,5-二取代吡唑化合物作为激酶抑制剂及其应用
JP2022539208A (ja) チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用
BR112017016278B1 (pt) Uso de um composto com atividade inibitória de btk ou um sal deste para produzir um agente preventivo e/ou terapêutico para a prevenção ou tratamento de uma doença imune
WO2026064705A1 (fr) Composés 5/5-5/6-bisaryles en tant qu'inhibiteurs de kinase activée par le facteur de croissance transformant béta
KR20200104336A (ko) 수용체 티로신 키나제 억제제의 Tyro3, Axl 및 Mertk (TAM) 패밀리로서의 헤테로고리 화합물
CN114026097B (zh) 取代的吡唑并喹唑啉酮化合物及其应用
WO2025072384A1 (fr) Composés 5/6-5/6-bisaryle utilisés en tant qu'inhibiteurs de tak1
EP3049400A1 (fr) Nouveaux inhibiteurs de pi3k/akt/mtor et leurs utilisations pharmaceutiques
CN118666846A (zh) 苯甲羰基吲哚类衍生物及其用途
EP4441052A1 (fr) Composés
CN117820305A (zh) 杂环取代喹唑啉及其制备方法和应用
HK40091563B (zh) 嘧啶酮类化合物及其用途